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Stereotactic body radiotherapy (SBRT) has emerged as a treatment for recurrent squamous
cell carcinoma of the head and neck in the field of prior radiation. We report a case of its
use in an human papilloma virus (HPV) positive patient with squamous cell carcinoma of
the right base of tongue.The patient had complete response to treatment and modest tox-
icities were noted.This represents encouraging results that SBRT is also useful for salvage
in patients with HPV positive disease.
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INTRODUCTION
Due to increasing rates of primary chemoradiation therapy, pre-
viously irradiated head and neck cancer patients with recurrent
disease are being encountered more and more frequently (Ang
and Sturgis, 2012). Stereotactic body radiotherapy (SBRT) has
recently been successfully implemented as a treatment option for
these patients.
Reports from case series cite encouraging statistics. Variable
tumor response rates from 40 to 80% have been demonstrated.
Toxicity estimates vary, with some series reporting low rates and
others significant rates of major complications (Heron et al., 2009)
(Cengiz). Consensus appears to be that SBRT is a viable option
with good short-term control rates and modest acute toxicity due
to increased precision and decreased duration of treatment (Heron
et al., 2009; Roh et al., 2009; Siddiqui et al., 2009; Rwigema et al.,
2011; Ang and Sturgis, 2012; Comet et al., 2012).
Human papilloma virus (HPV) is known to be a positive
prognostic indicator in head and neck cancer. HPV positive squa-
mous cell carcinomas of the head and neck are more amenable to
treatment. Patients typically present with less substantial tobacco
history. Five-year overall survival rates are above 80%. As a result,
there is more emphasis on preventing treatment-induced morbidi-
ties such as xerostomia and dysphagia. Different treatment strate-
gies may be useful in this population, as less aggressive treatment
may be adequate and could help prevent chronic complications
(Unger et al., 2010).
To our knowledge, the SBRT reirradiation literature to date
does not address HPV status. We report an HPV positive patient
treated with SBRT and discuss future areas of investigation.
CASE
FT initially presented to KUMC in 2009 with 20 pack-year smoking
history and symptoms of dysphagia, odynophagia, and right neck
mass for 2–3 months. He was 52 years of age and drank approx-
imately 21 alcoholic drinks weekly. He did not chew tobacco or
betel nut. Examination revealed a right level 2 neck mass and a
right tongue base mass. Imaging including CT and PET along with
endoscopy and biopsy lead to the diagnosis of T2N2aM0 squa-
mous cell carcinoma. The base of tongue mass measured 2.6 cm in
greatest dimension and the neck mass measured 1.9 cm× 2.5 cm.
Polymerase chain reaction testing for pan HPV DNA as well as
DNA for subtypes 6, 11, 16, 18, 31, and 33 was performed. Only
pan HPV DNA was positive, while subtypes 6, 11, 16, 18, 31, and
33 were negative individually. Therapeutic options were discussed,
including organ preserving concurrent chemotherapy/radiation
or laser excision. Given coexisting cardiovascular comorbidities
(aortic stenosis, hypertension) and possible compromise of voice
and swallow, plan was made for chemotherapy and radiation.
The patient completed a regimen of two cycles of induction
chemotherapy with Cisplatin and Docetaxel, followed by radiation
therapy and concurrent cetuximab, which was completed in Octo-
ber 2009. Radiotherapy was delivered using a delayed concomitant
boost technique with intensity modulated radiation therapy for
parotid sparing. A total of 72 Gy was delivered to the primary and
positive node. Approximately 1.8 Gy per fraction (54 Gy total) was
delivered daily 5 days per week for a total of 30 treatments. Treat-
ments were twice daily for the final two and a half weeks when a
boost dose consisting of 12 fractions of 1.5 Gy (18 Gy total) was
delivered in the afternoons, following the morning treatments of
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FIGURE 1 | CT neck of the neck with contrast, prior to treatment,
demonstrates a submucosal irregularity that was ultimately biopsied
and diagnosed as recurrent squamous cell carcinoma.
FIGURE 2 | After a 2-week course of stereotactic radiation, CT scan of
the neck with contrast showing complete response to therapy.
FIGURE 3 |The initial IMRT plan isodose lines (with the doses in the
upper left corner).
FIGURE 4 |The SRT plan isodose lines (with doses bottom right).
1.8 Gy. The total time elapsed was 6 weeks. On restaging PET, he
had hypermetabolic lymph nodes and underwent right modified
radical lateral neck dissection (levels two through four) in Decem-
ber 2009, showing microscopic squamous cell carcinoma in 3 out
of 15 nodes.
Our patient did well over the next year, but unfortunately CT
scan of the neck in September 2011 demonstrated an enlarged
peripherally enhanced soft tissue lesion within the submucosa of
the right tongue base measuring 1.3 cm× 1.5 cm× 1.1 cm, which
was concerning for recurrent disease (Figure 1). PET scan con-
firmed a focus of increased FDG uptake in the right tongue base
consistent with the lesion on CT scan that had SUV of 3.11.
He underwent endoscopy and biopsy in October 2011 and then
was diagnosed with a tongue base recurrence by CT-guided core
needle biopsy. His case was discussed by our institution’s Head
and Neck tumor board and recommendation was made for repeat
non-surgical treatment. Surgical resection is preferred at our insti-
tution for salvage of previously irradiated head and neck cancer. A
variety of techniques are employed, including conventional open
surgery, transoral laser surgery, and transoral robotic surgery. In
his case, concern regarding compromise of speech and swallowing
with surgery as well as his medical comorbidities prompted the
recommendation of reirradiation.
He subsequently had a fiducial placed in the tongue base mass
and underwent a course of hypofractionated image-guided stereo-
tactic radiation therapy (Figures 3 and 4). Daily cone beam CT
was used to reduce setup variability. Fifty gray was delivered in 10
fractions of 5 Gy per fraction on a daily basis Monday through Fri-
day. He tolerated this well. He returned to our clinic 3 months post
treatment. Clinically he continued to do well, with mild xerosto-
mia and chronic neck stiffness his only complaints. Comparison
of his pre and post treatment CT scans showed clear and com-
plete resolution of the submucosal tongue base mass (Figure 2).
Likewise, pre and post treatment PET scans showed resolution of
hypermetabolism in that location.
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Two months later he did develop a small ulcer in the orophar-
ynx at the posterior right tongue base and vallecula juncture at
the SBRT treatment site. Given the proximity to therapy, this was
suspected to be radiation induce mucositis and was treated con-
servatively as such. This improved and resolved with the aid of
lidocaine containing mouthwash over a 2-month period. Repeat
imaging 6 months post SBRT remained clear with no signs of
disease recurrence.
DISCUSSION
The list of cancers amenable to treatment by SBRT is rapidly grow-
ing. It utilizes advanced radiation techniques to generate a steep
dose gradient and allows for shortened treatment courses with
high dose per fraction. Recently, SBRT has become a viable option
for the treatment of recurrent head and neck cancer in previously
irradiated patients who are not surgical candidates. Although there
is currently limited data regarding its effectiveness in HPV posi-
tive patients, it can be expected to work well in this population
of patients who is currently thought of as more responsive to
traditional treatment.
There is debate about future direction of treatment of HPV pos-
itive head and neck cancer. As tobacco use declines, HPV positive
cancers will become increasingly predominant. Because HPV pos-
itive cancers have good prognosis and better response to treatment
compared to tobacco induced disease, current aggressive therapy
may need to be compared to less aggressive therapy which might
achieve similar disease outcome with less treatment related mor-
bidity. As previously described, SBRT may fit the requirements for
alternative therapy.
Early follow up of our patient shows encouraging results. With
regard to HPV status, our institution uses a separate probe with a
“cocktail” of different low- and high-risk types in addition to the
commonly available subtype testing.
Although he was negative for commonly tested low- and high-
risk HPV subtypes (6–11, 16–18, 31–33), positivity with our probe
was confirmed indicating the presence of HPV DNA in the patho-
logic specimen. He has had a complete response to therapy with
minimal toxicity. SBRT is shown in this case to be a possible alter-
native to surgical extirpation. Future studies should report on HPV
status. It will be interesting to see the evolution of the role of SBRT
in the treatment of HPV-related cancers.
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